Loading clinical trials...
Loading clinical trials...
A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 (Tesevatinib) in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Conditions
Interventions
Tesevatinib
Locations
11
United States
UCLA Medical Center
Los Angeles, California, United States
University of Colorado Denver
Denver, Colorado, United States
University of Kansas Medical Center
Kansas City, Kansas, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Mayo Clinic
Rochester, Minnesota, United States
Washington University School of Medicine
St Louis, Missouri, United States
Start Date
October 11, 2012
Primary Completion Date
February 8, 2019
Completion Date
February 8, 2019
Last Updated
November 8, 2022
NCT04534985
NCT03342742
NCT02903511
NCT04310319
NCT00410007
NCT01233869
Lead Sponsor
Kadmon, a Sanofi Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions